Preclinical Evaluation of the SARS-CoV-2 Mpro Inhibitor RAY1216

WuXi AppTec scientists contributed to a research article in the journal Nature Microbiology, which characterized a peptidomimetic inhibitor of the SARS-CoV-2 main protease (Mpro). In a human ACE2 transgenic mouse model, this inhibitor (designated RAY1216) exhibited antiviral activities against SARS-CoV-2 comparable to those of nirmatrelvir, but with improved pharmacokinetics.
Related Content
Tuberculosis is the leading cause of death from an infectious disease and is caused by Mycobacterium tuberculosis (MTB). Inosine-5′-monophosphate dehydrogenase...
VIEW RESOURCEToll-like receptor 8 (TLR8) plays an essential role in human antiviral immunity by recognizing ssRNA of viruses. Upon activation by...
VIEW RESOURCE